This news release announces the first two implantations of Bodycad’s Unicompartmental Knee System, knee replacement devices manufactured for individual patients using 3D printing technology and Bodycad’s “proprietary methods.”
Despite claims throughout that the 3D printed devices result in “a better fit” and “the potential for improved clinical results,” the company offers no data or evidence and does not reference any studies measuring the effectiveness of the devices.
The device has received clearance from the FDA in a letter stating the device is “substantially equivalent” to existing devices already in use. It should give readers pause that neither the news release or FDA letter indicate that any studies on patient outcomes were completed or even required. We offer a primer that describes the weak regulations governing approval of medical devices like this one.
The news release neglected to mention that one of the surgeons quoted received more than $90,000 in payments from two manufacturers of joint replacement devices during 2016.
Many people receiving knee replacements (or knee arthroplasty) are elderly and with our aging population, it’s expected the numbers of these procedures will keep growing. Estimates on the number of knee replacements performed each year in the US vary, but are projected to reach 3.4 million by 2030.
Devices manufactured specifically for individuals to replicate their existing knee joint could potentially improve clinical outcomes but studies of this device are still needed to show its benefit.
There is no mention of cost for the device itself or for the implantation surgery. The news release says manufacture is rapid, but gives no indication as to the actual time it takes, nor are the device’s component materials mentioned, so no estimation of materials costs can be made.
The cost for 3D printed knee replacements are undoubtedly higher than traditional replacements.
The news release states that a personalized knee joint would fit better and therefore provide better results. However, there is no data supporting how much better the device fits, how closely existing knee replacement devices do fit, nor is there any mention of how patients lives improved after receiving the implants. Did they have less pain? Increased mobility? Some measurement is needed here.
The news release does not mention any potential harms from knee replacement surgery in general or for the 3-D printed knee replacement specifically. There are risks associated with new medical devices and the risks increase when the device has not been tested.
The release doesn’t include any evidence. There are testimonials from two surgeons who implanted the two devices and a statement by Jean Robichaud, president of Bodycad, who said “These recent procedures reinforce a growing body of evidence that demonstrates the benefit of personalized restorations.” But no reference is provided for that evidence.
There is no disease mongering. A percentage of the aging population and some athletes will require knee replacement surgery.
While no funding sources are mentioned, it is obvious from the news release that Bodycad is the funding source of their device. There is also an obvious conflict of interest because the company wants to sell their product and the company controls the U.S. patent. But this is expected from a news release from a company touting its own product.
At least one of the surgeons quoted in the release has received funding from manufacturers of joint replacement devices. Dr. Brain Hamlin received $$87,737 from Smith & Nephew in 2016 and $8,127 from Depuy Orthopaedics, also in 2016, according to Open Payments, a federal transparency program.
These conflicts should have been included in the release.
While the news release does compare the 3-D printed device to conventional devices suggesting that personalized devices are better, there are no data showing that this is the case.
The whole point of the news release is to say that Bodycad can make personalized knee replacements and it has implanted two of them and it worked. By mentioning that the devices were cleared for use in the U.S. and Europe the company makes it clear they are available. It’s unknown, though, how many surgeons have been trained in the use of the devices.
The news release doesn’t establish novelty. In fact, it implies that other companies are making personalized knee replacement devices, but that theirs is better. The news release states, “The efficient, rapid, and highly automated process is the only one of its kind in the world that is impeccably integrated between software and modern manufacturing such as 3D printing.”
Companies have been developing customized joint replacement devices for about 25 years. Last year, a company called ConforMIS released results from its prospective study of 62 patients that received either its customized knee replacement product or a conventional device.
The release’s use of the word “revolutionary” is unjustified because 1) customized knee replacement devices are not unique to this company and 2) the release provided no evidence of its benefits.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like